c/o ETH Zürich FBTL
Schmelzbergstrasse 7, LFV D42
Rethinking Intestinal Therapy
About 20% of the population suffer from bowel-related diseases, causing a heavy burden for the patients’ lives as well as the healthcare system. It is increasingly evident, that this is just the tip of the iceberg and the microbiome is involved in the majority of chronic diseases related to metabolism or the immune system.
The scientific community agrees that the only curative treatment is to sustainably change microbiome composition, a challenge limited by the lack of understanding of the single microbes, their interactions and the diversity of these factors in the patient population. Fecal microbiota transplant (FMT) from a healthy donor to the patient is currently the only experimental treatment that uses the full potential of the microbiome transferring gut bacteria as a network and not as isolated bacteria.
„It’s a waste that we don’t use this organ of ours to get an integrated treatment for every patient.“ – Tomas de Wouters
PharmaBiome established a proprietary technology platform to isolate, culture and characterize the largely unknown and delicate gut microbes. Based on their functional interaction, PharmaBiome formulates them into pharmaceutical grade mixed cultures to sustainably modulate the gut’s microbiome and thereby treat microbiome-related diseases. Using this function-based approach the startup showed the potential of simplified mixes to unlock the therapeutic power of these trillions of bacteria.
The three founders are Tomas de Wouters, who has an engineering background and a PhD in microbiome biology, Florian Rosenthal, who holds a PhD in biology and profound knowledge of biochemistry and entrepreneurial experience and Manuel Banz, MSc ETH with a biology Master and experience in banking and finance.